StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
PFRM3.SA$6.86-2.70%
Fair $6.86+0.0%

PFRM3.SA

Profarma Distribuidora de Produtos Farmacêuticos S.A.

Healthcare / Medical DistributionSão Paulo

$6.86

-0.19 (-2.70%)

Fairly Valued+0.0%Fair Value $6.86Fund rank 34/100 · Data gapFallback financials|
SA 38/D
F-Score: 6/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 24% · confianza 25%

FCF escenarios

weak_data · normalized FCF $430.3M · quality 67.7/100

Data gap 34/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 74/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

38/100

D

Piotroski

6/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · PFRM3.SALocal privado en este navegador · Profarma Distribuidora de Produtos Farmacêuticos S.A.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$841M

P/E

8.0x

↓

EV/EBITDA

3.9x

↓

ROE

8.8%

↑

Gross Margin

15.3%

↓

Debt/Equity

1.04

↑
52-Week Range$7
$6$10

TradingView lightweight chart

PFRM3.SA price, volumen y niveles de valoración

Último $6.860Periodo -70.9%
Fair value: $6.860

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+13.6%

FCF CAGR

+54.9%

FCF margin

3.8%

FCF / Net income

3.62x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $11.45B · net income $118.9M · FCF $430.3M

2022-FY → 2025-FY

Gross margin

15.3%+0.6% pts

Operating margin

3.1%+0.4% pts

Net margin

1.0%+0.0% pts

FCF margin

3.8%+2.3% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$11.45B$11.45B$10.15B$8.66B$7.82B
Net Income$118.9M$118.9M$114.6M$70.4M$80.9M
EBITDA$518.8M$518.8M$446.8M$353.4M$331.8M
EPS0.970.970.930.570.66
Gross Margin15.3%15.3%15.0%14.9%14.7%
Operating Margin3.1%3.1%3.0%2.6%2.7%
Net Margin1.0%1.0%1.1%0.8%1.0%
Balance Sheet
Debt/Equity1.041.040.960.920.86
Current Ratio1.331.33———
Cash Flow
Free Cash Flow$430.3M$430.3M$469.0M$246.9M$115.8M
Returns
ROE8.8%8.8%8.8%5.6%6.8%
Valuation
P/E7.987.986.529.155.14
EV/EBITDA3.873.873.954.513.79
P/B0.630.630.570.520.35
Growth & Yield
Revenue Growth12.8%12.8%17.2%10.8%—
EPS Growth3.9%3.9%62.7%-13.0%—
Dividend Yield13.2%13.2%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

-14.4%

fácil

EPS terminal req.

$0.61

Spread vs growth

18.2%

5Y implied EPS CAGR

-5.4%

fácil

EPS terminal req.

$0.74

Spread vs growth

9.2%

10Y implied EPS CAGR

2.0%

fácil

EPS terminal req.

$1.19

Spread vs growth

1.8%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -7.8%

Total return

-7.8%

Start / end P/E

9.3x → 7.1x

EPS bridge

0.93 → 0.97

Residual

-0.9%

EPS growth+3.9%
Multiple rerating-23.9%
Dividend+13.2%
Residual / FX / buybacks / cross-term-0.9%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.